Pharmaceutical Policy In China
- 1 July 2008
- journal article
- Published by Health Affairs (Project Hope) in Health Affairs
- Vol. 27 (4), 1042-1050
- https://doi.org/10.1377/hlthaff.27.4.1042
Abstract
Contradictory goals plague China’s pharmaceutical policy. The government wants to develop the domestic pharmaceutical industry and has used drug pricing to cross-subsidize public hospitals. Yet the government also aims to control drug spending through price caps and profit-margin regulations to guarantee access even for poor patients. The resulting system has distorted market incentives, increased consumers’ costs, and financially rewarded inappropriate prescribing, thus undermining public health. Pharmaceuticals account for about half of total health spending in China, representing 43 percent of spending per inpatient episode and 51 percent of spending per outpatient visit. Yet some essential medicines are unavailable or of questionable quality.Keywords
This publication has 7 references indexed in Scilit:
- Who pays for health care in Asia?Journal of Health Economics, 2007
- Health service delivery in China: a literature reviewHealth Economics, 2007
- The availability and affordability of selected essential medicines for chronicl diseases in six low- and middle-income countriesPublished by WHO Press ,2007
- Price competition in the chinese pharmaceutical marketInternational Journal of Health Economics and Management, 2006
- The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitalsHealth Policy and Planning, 2005
- The Chinese experience of hospital price regulationHealth Policy and Planning, 2000
- Drug Prescribing in Rural Health Facilities in China: Implications for Service Quality and CostTropical Doctor, 1998